Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line
- 21 July 2015
- journal article
- Published by Springer Nature in Breast Cancer
- Vol. 23 (5) , 692-700
Abstract
Reactive oxygen species (ROS) are key players in the apoptotic effects induced by short-term tamoxifen treatment of breast cancer cells, but also in acquired resistance following long-term treatment. Whereas the use of the selective estrogen receptor down-regulator fulvestrant is promising, especially in patients who develop tamoxifen resistance, only few studies addressed its implication in the modulation of cellular redox status. The regulation of (pro/anti)-oxidant players were first investigated at the mRNA level in a MCF-7-derived cell line after short-term (24 h) estradiol treatment. Long-term anti-estrogen treated MCF-7 derived cell lines were also developed: 3 months of 4-hydroxytamoxifen alone (MCF7L-OHTLT) or followed by 3 months of fulvestrant (MCF7L-ICILT). Growth properties, hormone sensitivity, receptor content, ROS production and relative mRNA expression of pro or antioxidant enzymes were evaluated in these long-term treated cell lines. Short-term estradiol treatment showed a hormone sensitivity of Nox2, GPx1, GPx2 and SOD1 mRNA levels. The long-term fulvestrant treatment (3 months) of MCF7L-OHTLT led to a reduced level of ROS production accompanied with a drastic drop of the accessory protein p22phox mRNA. This ROS reduction, although not clearly related to antioxidant enzymes level, seems to be involved in fulvestrant sensitivity of long-term anti-estrogen treated cells, as suggested by the effects of antiradical tempol treatment. When compared to long-term 4-hydroxytamoxifen-treated breast cancer cells, addition of fulvestrant treatment was able to diminish ROS production and p22phox mRNA level, and made cells more sensitive to growth inhibition induced by tempol. These effects may be a valuable asset of the fulvestrant treatment.Keywords
This publication has 29 references indexed in Scilit:
- NADPH Oxidase Activation in Pancreatic Cancer Cells Is Mediated through Akt-dependent Up-regulation of p22Journal of Biological Chemistry, 2011
- FulvestrantDrugs, 2011
- The NADPH Oxidase Subunit p22phox Inhibits the Function of the Tumor Suppressor Protein TuberinThe American Journal of Pathology, 2010
- Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissuesFree Radical Research, 2009
- Redox Regulation of Cell SurvivalAntioxidants & Redox Signaling, 2008
- Diphenyleneiodonium induces ROS‐independent p53 expression and apoptosis in human RPE cellsFEBS Letters, 2006
- The nitroxide Tempol modulates anthracycline resistance in breast cancer cellsFree Radical Biology and Medicine, 2006
- Involvement of HP1α protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cellsFEBS Letters, 2005
- 17β‐oestradiol up‐regulates longevity‐related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFκB cascadeAging Cell, 2005
- Reactive oxygen species in tumor progressionFrontiers in Bioscience-Landmark, 2005